← Back to Clinical Trials
Recruiting NCT03980457

NCT03980457 Effects of Exoskeleton-Assisted Gait Training on Functional Rehabilitation Outcomes in Patients With Stroke

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT03980457
Status Recruiting
Phase
Sponsor University of Oklahoma
Condition Stroke
Study Type INTERVENTIONAL
Enrollment 50 participants
Start Date 2021-09-01
Primary Completion 2026-09-01

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 90 Years
Study Type INTERVENTIONAL
Interventions
Indego ExoskeletonStandard Rehabilitation

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 50 participants in total. It began in 2021-09-01 with a primary completion date of 2026-09-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The goal of this study is to determine the efficacy of electromechanical exoskeleton-assisted gait training on rehabilitation functional outcomes in patients with stroke undergoing therapy in an in-patient rehabilitation facility.

Eligibility Criteria

Inclusion Criteria: 1. All patients with acute hemorrhagic or ischemic stroke documented clinically and by neuroimaging. 2. Medically stable from a cardio-respiratory stand point so that they can participate in daily therapies. 3. Depressed patients will be included in the study 4. Patients able to stand alone 5. Patients able to provide a written informed consent, from cognitively intact patients (admission Mini Mental Scale Examination \[MMSE\] greater than or equal to 21). Exclusion Criteria: 1. Aphasic patients unable to communicate 2. Confused patients 3. Patients medically unstable 4. Patients unable to stand alone 5. Refusal to provide written informed consent

Contact & Investigator

Central Contact

Meheroz H Rabadi, MD, MRCPI

✉ rabadimh@gmail.com

📞 405-456-5298

Principal Investigator

Meheroz H Rabadi, MD, MRCPI

PRINCIPAL INVESTIGATOR

Affiliate; Oklahoma VA Health Care System

Frequently Asked Questions

Who can join the NCT03980457 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 90 Years, studying Stroke. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT03980457 currently recruiting?

Yes, NCT03980457 is actively recruiting participants. Contact the research team at rabadimh@gmail.com for enrollment information.

Where is the NCT03980457 trial being conducted?

This trial is being conducted at Oklahoma City, United States.

Who is sponsoring the NCT03980457 clinical trial?

NCT03980457 is sponsored by University of Oklahoma. The principal investigator is Meheroz H Rabadi, MD, MRCPI at Affiliate; Oklahoma VA Health Care System. The trial plans to enroll 50 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology